Imunon, Inc.
IMNNNasdaq
$1.83
↓ -3.2%Jul 17 close · end-of-day
Price
1Y↓ -71.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.2M
Enterprise Value
$4.4M
P/E
—
P/S
—
P/B
2.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$14.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
427.1%
ROIC
—
Debt / Equity
—
Net Cash
$4.8M
Return 1Y
-76.7%
Company profile
Celsion Corporation focuses on the development and commercialization of DNA-based immunotherapies and vaccines. Its product pipeline includes GEN-1 and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin.
- CEO
- Corinne L. Goff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New Jersey
- Website
- imunon.com
Management & directors
- Eylward SusanGeneral Counsel and Corp Sec
- Faller Douglas VincentChief Medical Officer
- Lindborg StacyPresident and CEO
- Tardugno Michael HExecutive Chairman of Board
Roles derived from SEC Form 4 filings.
Earnings
IMNN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.84↓ -73.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $500,000.00 | $500,000.00 | $500,000.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.5M | -$21.0M | -$24.9M | -$21.0M | -$19.1M | -$14.7M |
| Net income | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | $14.5M |
| Diluted EPS | — | — | -$5.03 | -$2.16 | -$16.94 | -$6.83 |
| Operating cash flow | -$15.6M | -$16.2M | -$23.1M | -$19.0M | -$18.9M | -$13.9M |
| Free cash flow | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3697.3% | -4201.4% | -4984.3% | — | — | — |
| Net margin | -4296.7% | -4153.9% | -7179.6% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.0M | -$5.0M | -$4.1M | -$4.1M | -$2.8M | -$3.5M | -$4.3M | -$4.3M |
| Net income | -$4.8M | -$4.8M | -$4.1M | -$4.1M | -$2.7M | -$3.4M | $24.8M | -$4.2M |
| Diluted EPS | -$7.64 | -$3.76 | -$5.02 | -$3.15 | -$2.15 | -$1.16 | -$0.37 | -$0.84 |
| Operating cash flow | -$4.5M | -$4.1M | -$4.4M | -$2.8M | -$3.0M | -$4.4M | -$3.7M | -$4.0M |
| Free cash flow | -$4.5M | -$4.1M | -$4.4M | -$3.1M | -$3.0M | -$4.4M | -$3.7M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 23, 2026
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Eylward Susan· General Counsel and Corp Sec | Sale | 920 | $1.88 | $1,729.60 | filing |
| 2026-07-06 | Eylward Susan· General Counsel and Corp Sec | Sale | 920 | $1.88 | $1,729.60 | filing |
| 2026-07-02 | Tardugno Michael H· Executive Chairman of Board | Award | 4,410 | $1.91 | $8,423.10 | filing |
| 2026-07-02 | Lindborg Stacy· President and CEO | Award | 2,534 | $1.91 | $4,839.94 | filing |
| 2026-07-02 | Faller Douglas Vincent· Chief Medical Officer | Award | 1,308 | $1.91 | $2,498.28 | filing |
| 2026-07-02 | Eylward Susan· General Counsel and Corp Sec | Award | 920 | $1.91 | $1,757.20 | filing |
| 2026-07-02 | Eylward Susan· General Counsel and Corp Sec | Award | 920 | $1.91 | $1,757.20 | filing |
| 2026-06-29 | Eylward Susan· General Counsel and Corp Sec | Sale | 11,800 | $1.75 | $20,673.60 | filing |
| 2026-06-25 | Lindborg Stacy· President and CEO | Award | 67,150 | $1.72 | $115,498.00 | filing |
| 2026-06-25 | Tardugno Michael H· Executive Chairman of Board | Award | 42,519 | $1.72 | $73,132.68 | filing |
| 2026-06-25 | Faller Douglas Vincent· Chief Medical Officer | Award | 21,896 | $1.72 | $37,661.12 | filing |
| 2026-06-25 | Eylward Susan· General Counsel and Corp Sec | Award | 14,696 | $1.72 | $25,277.12 | filing |
| 2026-06-18 | Tardugno Michael H· Executive Chairman of Board | Award | 4,629 | $1.82 | $8,424.78 | filing |
| 2026-06-18 | Lindborg Stacy· President and CEO | Award | 1,803 | $1.82 | $3,281.46 | filing |
| 2026-06-05 | Tardugno Michael H· Executive Chairman of Board | Award | 4,089 | $2.06 | $8,423.34 | filing |
| 2026-06-05 | Lindborg Stacy· President and CEO | Award | 1,593 | $2.06 | $3,281.58 | filing |
| 2026-05-22 | Dentzer James E | Award | 11,148 | $2.20 | $24,525.60 | filing |
| 2026-05-22 | Fritz Frederick J. | Award | 10,330 | $2.20 | $22,726.00 | filing |
| 2026-05-22 | Pellizzari Christine A | Award | 5,557 | $2.20 | $12,225.40 | filing |
| 2026-05-22 | Braun Donald P | Award | 5,011 | $2.20 | $11,024.20 | filing |
| 2026-05-22 | Tardugno Michael H· Executive Chairman of Board | Award | 3,484 | $2.20 | $7,664.80 | filing |
| 2026-05-22 | Lindborg Stacy· President and CEO | Award | 1,491 | $2.20 | $3,280.20 | filing |
| 2025-09-06 | Lindborg Stacy· President and CEO | Option exercise | 1,667 | $0.00 | $0.00 | filing |
| 2025-08-04 | Dentzer James E | Award | 3,318 | $9.20 | $30,525.60 | filing |
| 2025-08-04 | Fritz Frederick J. | Award | 3,161 | $9.20 | $29,081.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.